Immutep Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRRUF research report →
Companywww.immutep.com
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer.
- CEO
- Marc Voigt
- IPO
- 2012
- Employees
- 51
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $73.69M
- P/E
- -1.10
- P/S
- 15.54
- P/B
- 0.94
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -522.59%
- Op Margin
- -2052.18%
- Net Margin
- -1404.13%
- ROE
- -69.20%
- ROIC
- -122.10%
Growth & Income
- Revenue
- $5.04M · 31.28%
- Net Income
- $-61,434,165 · -43.82%
- EPS
- $-0.04 · -18.54%
- Op Income
- $-126,421,795
- FCF YoY
- -73.68%
Performance & Tape
- 52W High
- $0.33
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.18
- Beta
- 2.36
- Avg Volume
- 52.58K
Get TickerSpark's AI analysis on PRRUF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PRRUF Coverage
We haven't published any research on PRRUF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRRUF Report →